VISIOMED GROUP SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.19 EUR | +3.26% |
|
+0.21% | -32.86% |
| 03-26 | Visiomed: share price rises on 'record' 2023 results | CF |
| 02-13 | Visiomed: 38% increase in annual sales | CF |
| Sales 2021 | 7.18M 7.68M 10.49M | Sales 2022 | 14.44M 15.44M 21.11M | Capitalization | 98.55M 105M 144M |
|---|---|---|---|---|---|
| Net income 2021 | -4M -4.28M -5.85M | Net income 2022 | -5M -5.35M -7.31M | EV / Sales 2021 | 1.38 x |
| Net cash position 2021 | 1.62M 1.73M 2.36M | Net Debt 2022 | 3.26M 3.48M 4.76M | EV / Sales 2022 | 7.05 x |
| P/E ratio 2021 |
-1.33
x | P/E ratio 2022 |
-22.7
x | Employees | 73 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +3.26% | ||
| 1 week | +0.21% | ||
| Current month | -19.15% | ||
| 1 month | -13.95% | ||
| 3 months | -22.45% | ||
| 6 months | -19.15% | ||
| Current year | -32.86% |
1 week
0.18
0.21
1 month
0.180.24
Current year
0.180.31
1 year
0.180.59
3 years
0.080.65
5 years
0.082.71
10 years
0.08291.20
| Managers | Title | Age | Since |
|---|---|---|---|
Clement Pacaud
CEO | Chief Executive Officer | 34 | 01-21 |
| Investor Relations Contact | - | - | |
Thomas Picquette
SEC | Corporate Secretary | - | 22-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | - | - | |
| Director/Board Member | - | - | |
Thomas Picquette
SEC | Corporate Secretary | - | 22-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.19 | +3.26% | 951,897 |
| 24-04-25 | 0.184 | -1.81% | 1,739,032 |
| 24-04-24 | 0.1874 | -4.29% | 1,365,469 |
| 24-04-23 | 0.1958 | +4.71% | 1,539,347 |
| 24-04-22 | 0.187 | -1.37% | 764,819 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am
More quotes
Founded in 2007, Visiomed Group SA relies on a long experience to innovative healthcare technologies and services that will shape tomorrow's health and prevention.
The Group now has focused its activities on the Middle East since 2021 with the acquisition of Smart Salem, the first digital medical analysis centre accredited by the Dubai Health Authority (DHA) in the United Arab Emirates, 100% owned by Visiomed Group SA.
Visiomed Group SA is also stepping up its development in the region, with the creation of Smart Health, a joint venture which will drive the deployment of the group's innovative centers in Saudi Arabia.
| 1st Jan change | Capi. | |
|---|---|---|
| -32.86% | 59.69M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.36% | 26.25B | |
| +2.07% | 26.48B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- ALVMG Stock
